Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of CytomX Therapeutics Inc (NASDAQ: CTMX) closed at $1.21 in the last session, down -3.97% from day before closing price of $1.26. In other words, the price has decreased by -$3.97 from its previous closing price. On the day, 0.96 million shares were traded. CTMX stock price reached its highest trading level at $1.25 during the session, while it also had its lowest trading level at $1.17.
Ratios:
We take a closer look at CTMX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.04 and its Current Ratio is at 1.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on May 28, 2024, Upgraded its rating to Overweight and sets its target price to $3.50 from $2.25 previously.
On May 09, 2024, Wedbush Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $8.
Jefferies Upgraded its Hold to Buy on May 06, 2024, whereas the target price for the stock was revised from $2.50 to $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 20 ’24 when Landau Jeffrey B sold 4,181 shares for $1.23 per share. The transaction valued at 5,139 led to the insider holds 119,056 shares of the business.
BELVIN MARCIA sold 4,181 shares of CTMX for $5,139 on Aug 20 ’24. The SVP, Chief Scientific Officer now owns 175,648 shares after completing the transaction at $1.23 per share. On Aug 20 ’24, another insider, ROWLAND LLOYD A, who serves as the General Counsel of the company, sold 4,181 shares for $1.23 each. As a result, the insider received 5,139 and left with 130,797 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 98606176 and an Enterprise Value of -8384812. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.75. Its current Enterprise Value per Revenue stands at -0.066 whereas that against EBITDA is -0.981.
Stock Price History:
Over the past 52 weeks, CTMX has reached a high of $5.85, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is 13.10%, while the 200-Day Moving Average is calculated to be -22.84%.
Shares Statistics:
According to the various share statistics, CTMX traded on average about 1.11M shares per day over the past 3-months and 2540330 shares per day over the past 10 days. A total of 78.23M shares are outstanding, with a floating share count of 76.93M. Insiders hold about 1.69% of the company’s shares, while institutions hold 65.49% stake in the company. Shares short for CTMX as of 1731628800 were 4438441 with a Short Ratio of 4.01, compared to 1728950400 on 6066894. Therefore, it implies a Short% of Shares Outstanding of 4438441 and a Short% of Float of 5.71.
